Roche: Phase 3 study on Covid treatment misses target
(CercleFinance.com) - Roche said on Wednesday that an experimental treatment for Covid-19 did not meet the primary endpoint in a Phase 3 clinical trial.
The study, which evaluated the rheumatoid arthritis drug Actemra/RoActemra in hospitalised patients with severe Covid-19 associated pneumonia, did not meet the primary endpoint of improved clinical status, the drugmaker said.
In addition, the key secondary endpoints - which included patient mortality at week four - were not met.
On a brighter note, there was a positive trend in time to hospital discharge in patients treated with Actemra/RoActemra, Roche pointed out.
The biopharmaceutical company's shares were just about keeping afloat - down just 0.1% in Wednesday morning trading.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The study, which evaluated the rheumatoid arthritis drug Actemra/RoActemra in hospitalised patients with severe Covid-19 associated pneumonia, did not meet the primary endpoint of improved clinical status, the drugmaker said.
In addition, the key secondary endpoints - which included patient mortality at week four - were not met.
On a brighter note, there was a positive trend in time to hospital discharge in patients treated with Actemra/RoActemra, Roche pointed out.
The biopharmaceutical company's shares were just about keeping afloat - down just 0.1% in Wednesday morning trading.
Copyright (c) 2020 CercleFinance.com. All rights reserved.